Homeopathy for Chronic Non-specific Low Back Pain: Randomised, Double-Blind, Crossover, Placebo-Controlled Clinical Trial Investigating the Efficacy of the Biotherapic Lumbar Vertebra (BIOVERT Trial).
Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Deise Lilian Costa Dias et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomised, double-blind, crossover, placebo-controlled trial assessed short-term efficacy and safety of a standardised Lumbar Vertebra LM2 biotherapic in 120 participants with chronic non-specific low back pain. Participants received both the biotherapic and placebo in separate phases. Pain and disability improved within both treatment phases, but there were no statistically significant between-treatment differences for pain (p = 0.435) or disability (p = 0.840). Pain improvement did not reach the predefined minimal clinically important difference, and adverse events were mild and comparable. The trial demonstrated no specific effect of the biotherapic.
Key findings
- Pain improved within both treatment phases, but the between-treatment difference was not significant (p = 0.435).
- Disability improved within both phases, with no significant difference between biotherapic and placebo (p = 0.840).
- Pain change did not reach the predefined minimal clinically important difference; endpoint mean pain remained above the inclusion threshold.
- Adverse events were mild and comparable across the biotherapic and placebo groups.
Why it matters
The findings distinguish improvement during treatment from evidence of a treatment-specific effect: both interventions were associated with within-group gains, but the trial did not show that the biotherapic outperformed placebo. This is relevant when interpreting symptom changes in chronic low back pain, where the therapeutic setting, expectations and placebo responses may contribute to observed improvement.
What to keep in mind
The study evaluated short-term efficacy; the abstract does not report longer-term outcomes.